Nilotinib-induced hyperbilirubinemia: is it a negligible adverse event?
Kim
Min Kyoung
MK
Cho
Hee Soon
HS
Bae
Young Kyung
YK
Lee
Kyung Hee
KH
Chung
Hae-Sun
HS
Lee
Soo-Youn
SY
Hyun
Myung Soo
MS
D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D005260:Female; D014453:Glucuronosyltransferase / Q000235:genetics; D006579:Heterozygote; D006801:Humans; D006932:Hyperbilirubinemia / Q000139:chemically induced* / Q000235:genetics; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy* / Q000235:genetics; D008875:Middle Aged; D011110:Polymorphism, Genetic; D011743:Pyrimidines / Q000009:adverse effects* / Q000627:therapeutic use; D000099148:UGT1A1 Enzyme
D000970:Antineoplastic Agents; D014453:Glucuronosyltransferase; D011743:Pyrimidines; D000099148:UGT1A1 Enzyme; C498826:nilotinib